The title of his talk is " Seed-Amplification Assays: Windows into ALS and Kindred Diseases".

Qualsody/Toferson conceived by CNS Director Dr. Smith and developed in collaboration with Don Cleveland (UCSD), Tim Miller (WashU), and...

The open access version of "Chinese Translation and Validation of the Center for Neurologic Study Lability Scale" has been published in...

Nature Neurology Reviews has highlighted a publication authored by Dr. Smith and colleagues regarding the identification of sporadic ALS...

Dr. Smith has been appointed as a scientific advisor to the ALS Network.

The open access version of "Misfolded alpha-Synuclein in Amyotrophic Lateral Sclerosis (ALS): Implications for Diagnosis and Treatment"...

Research spearheaded by the Center and Amprion Pharmaceutical identified a sub-group of sporadic ALS patients in whom a self-replicating...

At the invitation of James Wymer, M.D., Dr. Smith presented Neurology Grand Rounds at the University of Florida at Gainesville....

La Jolla Light and San Diego Business Journal recently reported upon the approval of Qalsody (tofersen). See links below or the pdf file....

Tofersen, a drug pioneered by Dr. Smith alongside Ionis Pharmaceuticals (Frank Bennett), and UCSD (Don Cleveland), was approved by the...

Alzheimers & Dementia: The Journal of the Alzheimer's Association has accepted "Pathogenesis of Alzheimer's Disease: Involvement of the...

The United States Patent and Trademark Office has notified CNS that they will be issued a patent on December 27th, 2022, for several...

On Wednesday, November 2nd, Dr. Smith's abstract regarding alpha-synuclein seed-amplification was presented at the NEALS convention in...

The FDA is granting the Biogen/Ionis ALS therapy drug tofersen, specific to SOD1 ALS, priority review an should have a decision by...

The results from the Phase 3 VALOR Trial and Open-Label Extension were presented at the 20th meeting of the European Network for the Cure...

The abstract was submitted to the European Academy of Neurology for presentation at their annual meeting. It gives an overview of a...

The session entitled Guamanian ALS Parkinson's Dementia Complex was co-chaired by Dr. Richard Smith and his colleague Dr. Jeffery Kelly,...

Neurotherapeutics in the Era of Translational Medicine Speaker: Richard A. Smith, M.D. Director, Center for Neurologic Study La Jolla,...

Biogen and Ionis announced that BIIB080/IONIS-MAPTRx, an antisense drug, demonstrated robust time and dose-dependent lowering of tau...

The lecture will be given in November at the Methodist Hospital (Houston). The invitation was extended by Dr. Stanley Appel, Chair of the...